Condition: Ischemic Stroke · TIA · Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Two Dutch guidelines (Stroke and Cardiovascular Risk Management) provide conflicting advice on optimal statin treatment in older patients. In the SAFEST-cohort, the investigators will assess the impact of continuing versus discontinuing a statin in frail individuals aged 70 and above with a recent ischemic stroke or transient ischemic attack (TIA) on their health-related quality of life and MACE free survival during a two-year follow-up period.
This description comes directly from the study's public registry record.
Susanna R Prins, MSc · 0031 20 566 9111 · s.r.prins@amsterdamumc.nl
Birgit A Damoiseaux-Volman, PhD · 0031 20 566 9111 · b.a.damoiseaux@amsterdamumc.nl
Always discuss trial participation with your own doctor first.
| Flevoziekenhuis | Almere Stad, Netherlands | Recruiting |
| Amsterdam UMC, location AMC | Amsterdam, Netherlands | Recruiting |
| Catharina Ziekenhuis | Eindhoven, Netherlands | Recruiting |
| Isala Klinieken | Zwolle, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06785740